FDA Approves Three-Drug Combination Tablet for HIV-1

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

The FDA has approved Atripla, a fixed-dose combination of three previously approved antiretroviral drugs that is taken once a day in tablet form to treat HIV-1 infection.

ROCKVILLE, Maryland—The FDA has approved Atripla, a fixed-dose combination of three previously approved antiretroviral drugs that is taken once a day in tablet form to treat HIV-1 infection. Atripla consists of Sustiva (efavirenz, Bristol-Myers Squibb), approved in 1998; Emtriva (emtricitabine, Gilead Sciences), approved in 2003; and Viread (tenofovir disoproxil fumarate, Gilead) approved in 2001. A joint venture by Bristol-Myers Squibb and Gilead, the first if its kind in the area of HIV treatment, will market Atripla in the United States. Merck controls the rights to Sustiva in several parts of the world, and the three companies will cooperate in ensuring the medication is available to physicians and patients, the FDA said.

The trial submitted to support Atripla involved 244 adults infected with HIV-1, who received the three drugs contained in the new fixed-dose combination medication. At the end of the 48-week study, 80% of the participants achieved a marked reduction in their HIV count and a substantial increase in the number of healthy CD4 immune-system cells.

Recent Videos
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
6 experts are featured in this series.
6 experts are featured in this series.
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Related Content